Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication

被引：9

作者：

Skerlj, Renato ^{[1
]}

Bridger, Gary ^{[2
]}

Zhou, Yuanxi ^{[2
]}

Bourque, Elyse ^{[1
]}

McEachern, Ernest ^{[2
]}

Danthi, Sanjay ^{[1
]}

Langille, Jonathan ^{[2
]}

Harwig, Curtis ^{[2
]}

Veale, Duane ^{[2
]}

Carpenter, Bryon ^{[2
]}

Ba, Tuya ^{[2
]}

Bey, Michael ^{[2
]}

Baird, Ian ^{[2
]}

Wilson, Trevor ^{[2
]}

Metz, Markus ^{[1
]}

MacFarland, Ron ^{[2
]}

Mosi, Renee ^{[2
]}

Bodart, Veronique ^{[2
]}

Wong, Rebecca ^{[2
]}

Fricker, Simon ^{[1
]}

Huskens, Dana ^{[3
]}

Schols, Dominique ^{[3
]}

机构：

[1] Genzyme Corp, Waltham, MA 02451 USA

[2] Anormed Inc, Langley, BC V2Y 1N5, Canada

[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 03期

基金：

英国医学研究理事会;

关键词：

HIV-1; hERG; CCR5; chemokine receptor; LONG-QT SYNDROME; MARAVIROC; GO;

D O I：

10.1021/ml2002604

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing lipophilicity was the main design criteria used to identify compounds that did not inhibit the hERG channel, but subtle structural modifications were also important. Interestingly, within this series, compounds with low hERG inhibition prolonged the action potential duration (APD) in dog Purkinje fibers, suggesting a mixed effect on cardiac ion channels.

引用

页码：216 / 221

页数：6

共 50 条

[1] Discovery of potent, orally bioavailable CCR5 antagonists - 1.
Tagat, J
Nazareno, D
Vice, S
Lin, S
Steensma, R
Miller, M
Bauer, A
McCombie, S
Palani, A
Josien, H
Clader, J
Neustadt, B
Greenlee, W
Ganguly, A
Piwinski, J
Chan, TM
Evans, A
Dan, N
Baroudy, B
Endres, M
Strizki, J
Vantuno, N
Cox, K
Broske, L
Zhang, X
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U5 - U5
[2] Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
Skerlj, Renato
Bridger, Gary
Zhou, Yuanxi
Bourque, Elyse
McEachern, Ernest
Langille, Jonathan
Harwig, Curtis
Veale, Duane
Yang, Wen
Li, Tongshong
Zhu, Yongbao
Bey, Michael
Baird, Ian
Sartori, Michael
Metz, Markus
Mosi, Renee
Nelson, Kim
Bodart, Veronique
Wong, Rebecca
Fricker, Simon
Mac Farland, Ron
Huskens, Dana
Schols, Dominique
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 6950 - 6954
[3] Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
Skerlj, Renato
Bridger, Gary
Zhou, Yuanxi
Bourque, Elyse
Langille, Jonathan
Di Fluri, Maria
Bogucki, David
Yang, Wen
Li, Tongshuang
Wang, Letian
Nan, Susan
Baird, Ian
Metz, Markus
Darkes, Marilyn
Labrecque, Jean
Lau, Gloria
Fricker, Simon
Huskens, Dana
Schols, Dominique
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (08) : 2450 - 2455
[4] Design of Substituted lmidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication
Skerlj, Renato
Bridge, Gary
Zhou, Yuanxi
Bourque, Elyse
McEachern, Ernest
Metz, Markus
Harwig, Curtis
Li, Tong-Shuang
Yang, Wen
Bogucki, David
Zhu, Yongbao
Langille, Jonathan
Veale, Duane
Ba, Tuya
Bey, Michael
Baird, Ian
Kaller, Alan
Krumpak, Maria
Leitch, David
Satori, Michael
Vocadlo, Krystyna
Guay, Danielle
Nan, Susan
Yee, Helen
Crawford, Jason
Chen, Gang
Wilson, Trevor
Carpenter, Bryon
Gauthier, David
MacFarland, Ron
Mosi, Renee
Bodart, Veronique
Wong, Rebecca
Fricker, Simon
Schols, Dominique
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (20) : 8049 - 8065
[5] Discovery of potent, orally bioavailable CCR5 antagonists - 2.
Palani, A
Shapiro, S
Josien, H
Bara, T
Clader, J
Greenlee, W
Tagat, J
Steensma, R
McCombie, S
Neustadt, B
Pushpavanam, P
Chan, TM
Evans, A
Blythin, D
Ganguly, A
Piwinski, J
Dan, N
Baroudy, B
Endres, M
Strizki, J
Vantuno, N
Cox, K
Broske, L
Zhang, X
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U5 - U5
[6] Discovery of potent and orally bioavailable CCR5 antagonists: Part I
Wei, Robert G.
Chen, Binglong
Dunning, Laura
Ho, Elena
Jaroch, Stefan
Lee, Wheeseong
Onuffer, James
Subramanyam, Babu
Shen, Jun
Tseng, Jih-Lie
Ye, Bin
Gary, Phillips
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 596 - 596
[7] Orally bioavailable competitive CCR5 antagonists
Thoma, G
Nuninger, F
Schaefer, M
Akyel, KG
Albert, R
Beerli, C
Bruns, C
Francotte, E
Luyten, M
MacKenzie, D
Oberer, L
Streiff, MB
Wagner, T
Walter, H
Weckbecker, G
Zerwes, HG
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (08) : 1939 - 1955
[8] CCR5 inhibitors in HIV-1 therapy
Dorr, Patrick
Perros, Manos
EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
[9] A Novel Small-molecule CCR5 Agonist, ESN-196, with Potent R5 HIV-1 Activity
Ferain, Thierry
Schols, Dominique
Bernard, Jerome
Fraser, Graeme
ANTIVIRAL RESEARCH, 2009, 82 (02) : A23 - A24
[10] DESIGN AND SYNTHESIS OF POTENT, ORALLY BIOAVAILABLE HIV-1 PROTEASE INHIBITORS
KALDOR, SW
KALISH, V
DRESSMAN, BA
FRITZ, JE
HAMMOND, M
CROWELL, TA
TATLOCK, J
REICH, S
DAVIES, J
APPELT, K
SHETTY, B
SU, KS
CAMPANALE, KM
BURGESS, JA
LUBBENHUSEN, PP
BAXTER, AJ
MUESING, MA
HATCH, SD
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 17 - MEDI

← 1 2 3 4 5 →